A Phase II Study of Single Agent Brentuximab Vedotin in Relapsed/Refractory CD30 Low (<10%) Mature T Cell Lymphoma (TCL)
Case Comprehensive Cancer Center
Case Comprehensive Cancer Center
City of Hope Medical Center
City of Hope Medical Center
BeiGene
Northwestern University
University of Nebraska
Mayo Clinic
Shandong Provincial Hospital
Fred Hutchinson Cancer Center
Roswell Park Cancer Institute
University of Chicago
Barbara Ann Karmanos Cancer Institute
University of Texas Southwestern Medical Center
Wake Forest University Health Sciences
Royal Marsden NHS Foundation Trust
Fred Hutchinson Cancer Center
Fred Hutchinson Cancer Center
University of Washington
Fred Hutchinson Cancer Center
Fred Hutchinson Cancer Center
Mayo Clinic
National Cancer Institute (NCI)
National Cancer Institute (NCI)
City of Hope Medical Center
Singapore General Hospital
National Cancer Institute (NCI)
Northside Hospital, Inc.
National Cancer Institute (NCI)
Memorial Sloan Kettering Cancer Center
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Northside Hospital, Inc.
European Organisation for Research and Treatment of Cancer - EORTC
European Organisation for Research and Treatment of Cancer - EORTC
M.D. Anderson Cancer Center
Northside Hospital, Inc.
Case Comprehensive Cancer Center
Hoag Memorial Hospital Presbyterian
Fred Hutchinson Cancer Center
National Cancer Institute (NCI)